INTerpath-001 and Personalized mRNA Vaccination in Resected High-Risk Melanoma

Evaluation Form

35 Member Networks and Programs Receive Commendations in 2026 for Research Performance

November 19, 2026

Now Enrolling: EA2251 for Patients With Advanced Biliary Tract Cancer

November 19, 2026
Evaluation Form

35 Member Networks and Programs Receive Commendations in 2026 for Research Performance

November 19, 2026

Now Enrolling: EA2251 for Patients With Advanced Biliary Tract Cancer

November 19, 2026

INTerpath-001 and Personalized mRNA Vaccination in Resected High-Risk Melanoma

By Janice Mehnert, MD

For patients with high-risk melanoma, surgery can mark both an ending and a beginning. The visible cancer may be gone, but uncertainty often remains: could microscopic disease still be present, and will the melanoma return? INTerpath-001 matters because it addresses that uncertainty with an approach built around the individual patient rather than a generic tumor category. In my view, this is personalized cancer therapy at its best—not simply a new drug, but a way of using each patient’s own tumor biology to direct the immune system toward what makes that cancer unique.

INTerpath-001 is a randomized, double-blind, phase 3 study of intismeran autogene, previously known as V940 or mRNA-4157, combined with pembrolizumab after complete resection of high-risk cutaneous melanoma. Patients with stage IIB/IIC, III, or IV melanoma were randomized 2:1 to receive intismeran plus pembrolizumab or placebo plus pembrolizumab. The study’s primary endpoint was recurrence-free survival; secondary endpoints included distant metastasis-free survival, overall survival, safety, and patient-reported outcomes. 

What makes this treatment distinct is that it is made for the individual patient. Tumor and normal tissue are sequenced to identify neoantigens—molecular signatures created by mutations unique to the patient’s cancer and considered alongside that patient’s HLA type. Intismeran is designed to encode up to 34 of those neoantigens. In simple terms, it gives the immune system a personalized roadmap of what to recognize and attack. Pembrolizumab then helps keep T cells active by blocking the PD-1 pathway, which tumors can exploit to evade immune destruction. 

The trial also confronted a critical practical question: can a patient-specific treatment be delivered quickly enough to matter after surgery? Pembrolizumab began within 13 weeks of resection, while intismeran was manufactured and introduced when available. More than 99% of patients assigned to intismeran had product successfully manufactured, 91% had the maximum 34 neoantigens identified for treatment design, and the median time to the first intismeran dose was 64 days. This is a major achievement because it shows that personalization does not have to mean delay. 

At a median follow-up of 24.6 months, intismeran plus pembrolizumab reduced the risk of recurrence or death by 42% compared with pembrolizumab alone (hazard ratio, 0.58; 95% confidence interval, 0.45–0.75; P < 0.001). Recurrence-free survival was 82.2% with the combination, compared with 70.0% with pembrolizumab alone. The combination also reduced the risk of distant metastasis or death by 38%; distant metastasis-free survival was 88.5% versus 80.2%, respectively. 

These numbers are important, but their meaning is even more important. A recurrence is not merely a trial endpoint. For patients and families, it can mean renewed treatment, disruption, fear, and an uncertain future. Preventing recurrence and distant spread can preserve time, normalcy, and hope.

The added side effects—such as fever, injection-site reactions, fatigue, flu-like symptoms, and chills—were generally low grade and transient. Overall-survival data remain immature, and long-term follow-up is essential. 

INTerpath-001 provides a blueprint for future trials in lung cancer, bladder cancer, renal cell carcinoma, and other tumors. It shows that an individualized mRNA therapy can be designed, manufactured, and delivered at scale—and, most importantly, can improve clinically meaningful outcomes. 


Dr. Mehnert is associate director for clinical research at NYU Langone’s Perlmutter Cancer Center and holds a faculty appointment as professor in the Department of Medicine at New York University's Grossman School of Medicine. She is co-chair of the ECOG-ACRIN Cancer Research Group's Melanoma Committee.

Leave a Reply

Your email address will not be published. Required fields are marked *

Please DO NOT include personal medical information, diagnoses, treatment details, medical record numbers, or other sensitive health information in this form.